PTGER4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL120617	1.00	20/20
SCHEMBL238389	0.79	20/20
SCHEMBL196261	0.68	20/20
SCHEMBL196448	0.67	20/20
SCHEMBL196044	0.51	20/20
SCHEMBL196041	0.57	19/20
SCHEMBL253776	0.54	19/20
SCHEMBL197416	0.52	19/20
SCHEMBL197949	0.51	18/20
SCHEMBL196388	0.55	17/20
SCHEMBL197059	0.52	17/20
SCHEMBL247942	0.55	16/20
SCHEMBL196279	0.57	15/20
SCHEMBL242586	0.51	12/20
SCHEMBL124112	0.64	11/20
SCHEMBL124113	0.64	11/20
SCHEMBL124114	0.64	11/20
SCHEMBL125666	0.64	11/20
SCHEMBL126529	0.52	11/20
SCHEMBL126530	0.52	11/20

Clinical trials — most relevant to PTGER4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation	PHASE4	WITHDRAWN
Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?	PHASE4	COMPLETED
n-3 Polysaturated Fatty Acids-rich Diet in Psoriasis	PHASE4	COMPLETED
Montelukast in Parkinson Disease	PHASE2/PHASE3	RECRUITING
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
Aspirin for Uncontrolled Asthma	PHASE3	COMPLETED
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA	PHASE2/PHASE3	COMPLETED
European Celecoxib Trial in Primary Breast Cancer	PHASE3	COMPLETED
Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine	PHASE2	WITHDRAWN
EP4-receptor Antagonism and Prostaglandin E2 (PGE2) in a Human Headache Model	PHASE1/PHASE2	COMPLETED
A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis	PHASE2	COMPLETED
HTL0039732 in Participants With Advanced Solid Tumours	PHASE1/PHASE2	RECRUITING
Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention	PHASE2	COMPLETED
Esomeprazole Magnesium With or Without Aspirin in Preventing Esophageal Cancer in Patients With Barrett Esophagus	PHASE2	COMPLETED
Investigation the Effect of Montelukast in COVID-19	PHASE2	UNKNOWN
Changes in Biomarkers Using Prostaglandin Inhibitors	PHASE1/PHASE2	COMPLETED
Celebrex for Pain Relief After Oral Surgery	PHASE2	COMPLETED
MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)	EARLY_PHASE1	RECRUITING
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
PGE2/IL-22 Pathway in Various Forms of Eczema	nan	COMPLETED
Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses	nan	COMPLETED
The Effectiveness of Montelukast on Atopic Dermatitis in Koreans	nan	COMPLETED
Investigation of Lipoxin A4, Annexin A1 and Interleukin-1 Beta Levels in Individuals With Periodontitis.	nan	COMPLETED
Leukotrienes Pathway in Chinese Children With Sleep-disordered Breathing	nan	UNKNOWN
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Inflammation Impact on Pain in Knee Osteoarthritis	nan	COMPLETED
Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture	nan	UNKNOWN
Extracorporeal Shock Wave Therapy in the Treatment of Primary Dysmenorrhea	nan	COMPLETED
Association and Mechanism Between Cyclooxygenase-2 and Interleukin-6 in Gastric Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTGER4 binder may also engage these)

Protein	Name	Similarity
Q95KZ0	—	1.000	Q95KZ0 →
P32240	—	1.000	P32240 →
Q8MJ08	—	1.000	Q8MJ08 →
Q28691	—	0.998	Q28691 →
P43114	—	0.995	P43114 →
P46069	—	0.985	P46069 →
P34979	—	0.981	P34979 →
P56490	—	0.978	P56490 →
Q9N2A4	—	0.977	Q9N2A4 →
Q62053	—	0.977	Q62053 →
PTGER3	Prostaglandin E2 receptor EP3 subtype	0.976	landscape →
Q5IS98	—	0.975	Q5IS98 →
CHRM5	Muscarinic acetylcholine receptor M5	0.975	landscape →
P08911	—	0.975	P08911 →
P11483	—	0.974	P11483 →
P41984	—	0.973	P41984 →
Q5IS53	—	0.973	Q5IS53 →
P34980	—	0.973	P34980 →
P08483	—	0.973	P08483 →
Q9N2A2	—	0.973	Q9N2A2 →
P50131	—	0.972	P50131 →
CHRM3	Muscarinic acetylcholine receptor M3	0.972	landscape →
Q920H4	—	0.971	Q920H4 →
P30557	—	0.971	P30557 →
Q9ERZ3	—	0.971	Q9ERZ3 →
Q9N2A3	—	0.970	Q9N2A3 →
Q98895	—	0.970	Q98895 →
Q5U431	—	0.970	Q5U431 →
Q9XT82	—	0.969	Q9XT82 →
GPR39	G-protein coupled receptor 39	0.969	landscape →